Title : Nimbolide, a Neem Limonoid, Inhibits Angiogenesis in Breast Cancer by Abrogating Aldose Reductase Mediated IGF-1/PI3K/Akt Signalling.

Pub. Date : 2022

PMID : 35125086






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Nimbolide, a Neem Limonoid, Inhibits Angiogenesis in Breast Cancer by Abrogating Aldose Reductase Mediated IGF-1/PI3K/Akt Signaling. nimbolide aldo-keto reductase family 1 member B Homo sapiens
2 Molecular docking and simulation, overexpression, and knockdown experiments were performed to determine whether nimbolide targets AR and IGF-1R. nimbolide aldo-keto reductase family 1 member B Homo sapiens
3 RESULTS: Nimbolide inhibited AR with consequent blockade of the IGF-1/PI3K/Akt and HIF-1 /VEGF signaling circuit by influencing the phosphorylation and intracellular localisation of key signaling molecules. nimbolide aldo-keto reductase family 1 member B Homo sapiens
4 Downregulation of DNMT-1, HDAC-6, miR-21, HOTAIR, and H19 with upregulation of miR-148a/miR-152 indicated that nimbolide regulates AR and IGF-1/PI3K/Akt signaling via epigenetic modifications. nimbolide aldo-keto reductase family 1 member B Homo sapiens
5 Coadministration of nimbolide with metformin and the chemotherapeutic drugs tamoxifen/cisplatin displayed higher efficacy than single agents in inhibiting IGF-1/PI3K/Akt/AR signaling. nimbolide aldo-keto reductase family 1 member B Homo sapiens